Claudio Brancelli

University of Verona, Onze Lieve Vrouwziekenhuis Hospital

Papers

4

Total Citations

46

H-Index

3

About

Dr. Claudio Brancelli is a pioneering urologic surgeon and researcher at the forefront of robotic surgery innovation. His work centers on comparative effectiveness and next-generation robotic platforms for radical prostatectomy, with a particular focus on intraoperative performance metrics, surgical timing, and user satisfaction. Dr. Brancelli leads the landmark COMPAR-P Trial series, which provides the first rigorous head-to-head comparisons of emerging robotic systems—including Hugo RAS, Versius, and the Toumai® system—against the established DaVinci Xi. His 2024 study on Hugo RAS versus DaVinci Xi (36 citations) offers granular data on malfunction rates and complications, while his 2025 report on the first European telesurgery with the Toumai® system (5 citations) represents a groundbreaking step toward remote surgical care. Additionally, his validation of Briganti’s 2012 nomogram in over 500 intermediate-risk patients (3 citations) demonstrates his commitment to refining risk stratification in prostate cancer. With over 46 cumulative citations in just two years, Dr. Brancelli’s work is shaping the future of robot-assisted surgery, providing evidence that guides platform selection and improves patient outcomes.

Research Focus

Key Achievements

3
H-Index
4
Papers
46
Total Citations
12
Avg Citations/Paper
🏆 Most Cited Paper
Intraoperative Performance of DaVinci Versus Hugo RAS During Radical Prostatectomy: Focus on Timing, Malfunctioning, Complications, and User Satisfaction in 100 Consecutive Cases (the COMPAR-P Trial)
36 citations · 2024
📈 Most Prolific Year: 2024 (2 Papers)
🤝 Key Collaborators: 47
🏛 Institutions: University of Verona, Onze Lieve Vrouwziekenhuis Hospital

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago